Thermo Fisher Scientific
-
Thermo Fisher Adds Real-World Evidence to Remit Via $912M CorEvitas Acquisition
CorEvitas brings Thermo Fisher Scientific registries that gather data about how approved therapies are working in the real world. The acquisition will complement PPD, the contract research organization that Thermo Fisher purchased in 2021.
-
Thermo Fisher bets big on blood cancer, immune diagnostics with $2.6B Binding Site buyout
Thermo Fisher Scientific’s acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers and immune system disorders. It’s Thermo Fisher’s biggest acquisition since its 2021 buyout of contract research organization PPD.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Consumer / Employer, Patient Engagement, Pharmacy
2 collaborations – CVS Health with Medable, and Thermo Fisher Scientific with Medidata Acorn AI – seek to improve clinical trials
CVS MinuteClinic providers will use Medable’s software platform to improve patient access, engagement and retention during clinical trials. Meanwhile, Thermo Fisher Scientific and Medidata Acorn AI announced a collaboration to develop an application that combines patient recruitment and site performance data for clinical trials.
-
Thermo Fisher’s $21B deal for PPD gives it missing piece in drug development cycle
Thermo Fisher Scientific sells laboratory equipment used in drug research and it also offers manufacturing services for experimental and commercialized drugs. By acquiring PPD, Thermo Fisher says it will gain capabilities in the growing global market of clinical trial services.
-
Hospitals, Diagnostics, Health Services, Payers
Healthcare deals dip in 2020, but not as much as expected
Healthcare mergers decreased in the first half of 2020, but not to the extent expected as a result of the Covid-19 pandemic. Reports by Pricewaterhouse Coopers and Kaufman Hall showed a decline in mergers and acquisitions, but still reported sustained interest from buyers
-
Thermo Fisher gets emergency use authorization for Covid-19 diagnostic
The company said Monday that it had received the EUA from the Food and Drug Administration Friday, the same day that Swiss drug and diagnostics maker Roche received a similar nod for its coronavirus test.
-
How have these firms making Covid-19 news fared as stock markets have tanked?
While all these companies have been involved in developing testing, vaccines and drugs for SARS-CoV-2, fears related to the global coronavirus pandemic have taken their toll on them as well as firms in other sectors.
-
Thermo Fisher, J&J partner on next-generation sequencing diagnostic for cancer clinical trials
The deal will focus in particular on developing an NGS-based companion diagnostic to aid enrollment in clinical trials, especially for non-small cell lung cancer. Thermo Fisher signed a similar deal with Eli Lilly in September.
-
Thermo Fisher Scientific to acquire Qiagen, a maker of coronavirus diagnostics, in $11.5B deal
The deal between the two diagnostics giants, announced Tuesday, includes Thermo Fisher’s assumption of $1.4 billion in Qiagen’s debt. Qiagen has been developing diagnostics for detecting the novel coronavirus SARS-CoV-2.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Thermo Fisher aims to make next-gen sequencing more accessible to community hospitals
The biotechnology product development company announced the launch of its Ion Torrent Genexus System at the Association for Molecular Pathology’s annual meeting.
-
Thermo Fisher to buy gene therapy contract manufacturer Brammer Bio for $1.7B
Brammer specializes in contract services for viral vector-based gene therapies. Panelists at a conference last week stressed the importance of manufacturing for gene therapy investors.
-
What ever happened to the NantHealth-Independence Blue Cross sequencing partnership?
In January 2016, Independence Blue Cross and NantHealth announced the nation’s first coverage for a whole genome sequencing and proteome molecular diagnostic platform, but it’s mostly slipped under the radar since then. What’s going on?
-
CMS gives a big boost to broad genomic tests by widening coverage for sequencing
Foundation Medicine and ThermoFisher Scientific are big beneficiaries of CMS widening its coverage and making a national coverage decision for next-generation sequencing of metastatic, Stage 3 or 4 and other cancers.
-
Morning Read: Affymetrix mulls new bid, SCOTUS hears ACA contraception case
Plus, Paul Allen puts $100 million into high-risk biotech research, more California hospitals hit by ransomware and Roger Daltrey pushes 21st Century Cures legislation.
-
Morning Read: Affymetrix rejects the latest takeover bid meant to derail Thermo Fisher’s offer
Also, the latest hospital cyber attack (a ransomware attack), Zika gets political, a poll on the best kind of HIMSS keynotes, and the Valeant obituaries are rolling in.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
